Revolution Medicines Officer Sells Shares Under Rule 10b5-1 Plan
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Revolution Medicines, Inc. ($RVMD) Form 4 Insider Filing Insider: Anthony Mancini (Chief Global Commercialization Officer) Transaction: Sold 1,764 shares of Common Stock at $196.94 per share ($347,402 total value) Transaction Date: September 18, 2026 Post-Transaction Holdings: 40,352 shares (Direct) Note: Conducted under a pre-established Rule 10b5-1 trading plan adopted June 11, 2026.
Comprehensive Analysis
Executive Summary
On September 22, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. ($RVMD), filed a Form 4 reporting the open-market sale of 1,764 shares of common stock at a price of $196.94 per share, generating gross proceeds of approximately $347,402.
Transaction Details
- Date of Transaction: September 18, 2026
- Security: Common Stock
- Transaction Code: S (Open-market sale)
- Shares Sold: 1,764
- Execution Price: $196.94
- Total Value: $347,402.16
- Post-Transaction Holdings: 40,352 shares directly owned
Trading Significance
The trading significance is assessed as Low. The disposition represented approximately 4.2% of Mr. Mancini's direct holdings prior to the trade (42,116 shares). Furthermore, the transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2026, indicating routine scheduled diversification rather than a discretionary signal on company performance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.